Longevity
SLU-PP-332
Metabolic
44
Amino acids
Molecular weight
Peptide
Type
Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.
Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.
2-8°C refrigerated for research use
Research only - not approved for human use
NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP)
No human protocols established
Exercise mimetic effects without physical activity
12% weight loss in 28 days
70% increased endurance
25% enhanced fatty acid oxidation
Improved insulin sensitivity
Reduced hepatic steatosis
Cardiac protection
Reversal of age-related mitochondrial dysfunction
This peptide is still gaining traction in the community.
Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesView the scientifc details of SLU-PP-332.
44
Amino Acids
SLU-PP-332
Glu
Glu
Position 1
His
His
Position 2
Tyr
Tyr
Position 3
Asp
Asp
Position 4
Arg
Arg
Position 5
Pyl
Pyl
Position 6
?
?
Position 7
Tyr
Tyr
Position 8
Asn
Asn
Position 9
Asn
Asn
Position 10
Ala
Ala
Position 11
Pro
Pro
Position 12
His
His
Position 13
Thr
Thr
Position 14
His
His
Position 15
Ala
Ala
Position 16
Leu
Leu
Position 17
Glu
Glu
Position 18
Asn
Asn
Position 19
Tyr
Tyr
Position 20
Leu
Leu
Position 21
Met
Met
Position 22
Glu
Glu
Position 23
Thr
Thr
Position 24
His
His
Position 25
Tyr
Tyr
Position 26
Leu
Leu
Position 27
Glu
Glu
Position 28
Asn
Asn
Position 29
Glu
Glu
Position 30
Asx
Asx
Position 31
Glu
Glu
Position 32
Asn
Asn
Position 33
Glx
Glx
Position 34
Pyl
Pyl
Position 35
His
His
Position 36
Tyr
Tyr
Position 37
Asp
Asp
Position 38
Arg
Arg
Position 39
Ala
Ala
Position 40
Glx
Glx
Position 41
Ile
Ile
Position 42
Asp
Asp
Position 43
Glu
Glu
Position 44
Research compound - IP injection in animals only. No human administration protocols established.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Standard Metabolic Protocol | 50 | 2 week range | Intraperitoneal injection (IP) |
| Acute Exercise Enhancement | 50 | 1 week range | Intraperitoneal injection (IP) |
| Extended Treatment | 50 | 4 week range | Intraperitoneal injection (IP) |
Materials needed:
Steps to reconstitute
The SLU-PP-332 Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
Dosing tools
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Based on your vial and dilution inputs.
SLU-PP-332
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg SLU-PP-332 vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Note: Triple agonist; microdose for fewer side effects
Research suggestions of SLU-PP-332 interactions with other common peptides and substances.
Weight
5am
Longevity
COMPATIBLE
Distinct mechanisms (ERR agonism vs NNMT inhibition) likely complementary without known interactions.
Weight
ipa
Growth
COMPATIBLE
May preserve lean muscle during SLU-PP-332-induced fat loss through GH pathway.
Longevity
nad
Metabolic
SYNERGISTIC
Complementary mitochondrial pathways - SLU-PP-332 increases biogenesis while NAD+ supports energy production.
Weight
sem
Metabolic
MONITOR
Combining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely.
Weight
tir
Metabolic
MONITOR
Different mechanisms affecting weight loss and metabolism - combination could have additive effects.
Monitor: Be careful when combining SLU-PP-332 with Semaglutide, Tirzepatide.
NOT FOR HUMAN USE - no approved human dose
No human clinical trials conducted
Potential interaction with diabetes medications
Severe hypoglycemia (especially with diabetes medications)
Any cardiovascular symptoms (chest pain, palpitations, shortness of breath)
Signs of liver dysfunction (jaundice, dark urine, severe abdominal pain)
Kidney problems (reduced urination, swelling, severe back pain)
Severe headaches or neurological symptoms
Allergic reactions (rash, hives, difficulty breathing, swelling)
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
SLU-PP-332 is an emerging compound
SLU-PP-332
SLU-PP-332 is an emerging compound
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Diet-induced obese mice, 50 mg/kg IP twice daily, 28 days: 12% body weight loss, 25% fatty acid oxidation increase, improved glucose tolerance, reduced hepatic steatosis.
2024
Synthetic ERRα/β/γ Agonist Induces Acute Aerobic Exercise Response
Multiple mouse models, 50 mg/kg IP: 70% increase in running time, 45% increase in running distance, increased type IIa oxidative muscle fibers.
2023
Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction in Aging Kidney
21-month-old mice, 8-week treatment: Reversed age-related kidney decline, reduced albuminuria, prevented podocyte loss, restored mitochondrial architecture.
2023
Cardiac Protective Effects of Pan-ERR Agonists
Heart failure models, 6-week treatment: Improved ejection fraction, ameliorated cardiac fibrosis, improved survival, enhanced mitochondrial ultrastructure.
2021